1. Alnylam reported strong Q1 results with AMVUTTRA approval driving initial success. 2. The launch is progressing well, indicating positive market reception.
AMVUTTRA's approval may significantly enhance revenue streams, as seen with recent similar biotech successes like Regeneron's Eylea that uplifted their stock prices after approvals.
The FDA approval and Q1 results directly indicate strong performance and product reception, critical for ALNY's stock movement.
Immediate effects from the launch are expected in the next weeks to months, with revenues potentially reflecting this quickly as patient access increases.